Follow us:

For Investors

 

Highlights:

  • InspireMD addresses a growing, $1.8B market
  • Target market has limited competition
  • Aging population and desire for less invasive therapies create favorable growth demographics

 

InspireMD to Present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25th at 11am (EST)

 

 

 

Summary:

InspireMD Ltd. is a high growth medical device company focusing on the development and commercialization of its proprietary stent platform technology: MGuard™.

 

InspireMD has created a unique, patent-pending mesh net technology that wraps a stent, providing embolic protection (preventing Major Adverse Cardiac Events (MACE) by filtering debris) and reducing vessel injury by spreading strut pressure. MGuard™ is delivered with no change to the current procedure and is well-accepted by physicians. MGuard™ has been implanted in thousands of patients, and in clinical trials it has shown a more than 50% reduction in MACE compared with traditional bare metal stents.

ASTUDIO | Design & Development